Development of neuroinflammmation positron tracer and clinical application in inflammatory demyelinating diseases of central nerve system and neurodegenerative diseases

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069691

Enrollment

Unknown

Registered

2023-03-23

Start date

2023-03-27

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory demyelinating diseases of central nerve system and neurodegenerative diseases

Interventions

RRMS group:[11C]-PBR28

SPMS group:[11C]-PBR28

Healthy control group:[11C]-PBR28

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: MS diagnostic criteria refer to MacDnold diagnostic criteria revised in 2017; MS inclusion criteria: 1) voluntary subjects, patients or their legal representatives signed informed consent, 2) age: 18 ~ 75 years old, including the cut-off value; , 3) no MR Contraindications, 4) voluntary follow-up. With reference to Petersen and other diagnostic criteria for AD patients, the inclusion criteria of AD subjects included: 1) the subjects or their family members complained of obvious memory impairment; 2) Objective memory impairment (such as object memorization, recall, delayed memory, etc.); 3) CDR>=1.0; 4) MMSE 11-23 points; 5) Meet DSM IV and NINCDS-ADRDA criteria for Alzheimer's disease dementia. Healthy control group included: 1) overall health status; 2) There are no complaints of memory impairment. Cognitive function was normal by the combined screening of MMSE (28-30 points) and MoCA (26-30 points).

Exclusion criteria

Exclusion criteria: 1) History of stroke, HIS > 4; 2) Alcohol addiction; 3) Major mental illnesses: including anxiety disorders, emotional disorders, major psychosis, or drug-induced psychosis; 4) Neurological diseases: including brain tumors, craniocerebral trauma, multiple sclerosis, epilepsy, etc.; 5) Patients with serious medical conditions who are currently using respiratory drugs, cardiovascular drugs, anticonvulsants or psychoactive substances; 6) People with severe hearing and visual impairment.

Design outcomes

Primary

Measure	Time frame
[11C]-PBR28;Pharmacokinetic parameters;Regional distribution characteristics in the brain;	—

Secondary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactRuimin Wang

Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital

wrm@yeah.net13501151740

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026